Skip to main content
Contact Us
Subscribe
E-Edition
59°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by OS Therapies
OS Therapies to Present at The Spartan Capital Investor Conference
November 04, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
October 30, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
October 28, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies to Present at the LD Micro Main Event XVII
October 24, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
October 17, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
October 03, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
September 13, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
September 05, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
August 29, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
August 22, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Clarifies CUSIP of Common Stock
August 22, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
August 19, 2024
From
OS Therapies
Via
Business Wire
Tickers
OSTX
OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121 in Recurred, Resected Osteosarcoma with OST-HER2 (Listeria monocytogenes) for Delay or Prevention of Recurrence
September 26, 2023
From
OS Therapies
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.